fortekor plus
elanco gmbh - benazepril hydrochloride, pimobendan - ace inhibitors, combinations - dogs - for the treatment of congestive heart failure due to atrioventricular valve insufficiency or dilated cardiomyopathy in dogs.
lojuxta
amryt pharmaceuticals dac - lomitapide - hypercholesterolemia - lipid modifying agents - lojuxta is indicated as an adjunct to a low‑fat diet and other lipid‑lowering medicinal products with or without low-density-lipoprotein (ldl) apheresis in adult patients with homozygous familial hypercholesterolaemia (hofh). genetic confirmation of hofh should be obtained whenever possible. other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g. nephrotic syndrome, hypothyroidism) must be excluded.,
ozcrop clethodim 360 ec herbicide
oz crop pty ltd - clethodim; liquid hydrocarbon - emulsifiable concentrate - clethodim cyclohexanediones active 360.0 g/l; liquid hydrocarbon solvent other 570.0 g/l - herbicide
platinum xtra 360 herbicide
adama australia pty limited - clethodim; liquid hydrocarbon - emulsifiable concentrate - clethodim cyclohexanediones active 360.0 g/l; liquid hydrocarbon solvent other 534.0 g/l - herbicide
lojuxta 10 mg
medison pharma ltd - lomitapide as mesylate - capsules - lomitapide as mesylate 10 mg - lomitapide - an adjunct to a low-fat diet and other lipid-lowering treatments, including ldl apheresis where available, to reduce low-density lipoprotein cholesterol (ldl-c), total cholesterol (tc), apolipoprotein b (apo b), and non-high-density lipoprotein cholesterol (non-hdl-c) in patients with homozygous familial hypercholesterolemia (hofh).
lojuxta 20 mg
medison pharma ltd - lomitapide as mesylate - capsules - lomitapide as mesylate 20 mg - lomitapide - an adjunct to a low-fat diet and other lipid-lowering treatments, including ldl apheresis where available, to reduce low-density lipoprotein cholesterol (ldl-c), total cholesterol (tc), apolipoprotein b (apo b), and non-high-density lipoprotein cholesterol (non-hdl-c) in patients with homozygous familial hypercholesterolemia (hofh).
lojuxta 5 mg
medison pharma ltd - lomitapide as mesylate - capsules - lomitapide as mesylate 5 mg - lomitapide - an adjunct to a low-fat diet and other lipid-lowering treatments, including ldl apheresis where available, to reduce low-density lipoprotein cholesterol (ldl-c), total cholesterol (tc), apolipoprotein b (apo b), and non-high-density lipoprotein cholesterol (non-hdl-c) in patients with homozygous familial hypercholesterolemia (hofh).
koselugo 10 mg
astrazeneca (israel) ltd - selumetinib as hyd-sulfate - hard capsule - selumetinib as hyd-sulfate 10 mg - selumetinib - koselugo is indicated for the treatment of pediatric patients 2 years of age and older withneurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn).
koselugo 25 mg
astrazeneca (israel) ltd - selumetinib as hyd-sulfate - hard capsule - selumetinib as hyd-sulfate 25 mg - selumetinib - koselugo is indicated for the treatment of pediatric patients 2 years of age and older withneurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn).
anandron
sanofi-aventis australia pty ltd - nilutamide -